top of page
Search

New Medicare Changes Limit the Cost of Insulin

  • Writer: Raye Elaine, BCPA
    Raye Elaine, BCPA
  • Oct 7, 2022
  • 1 min read

Many people may not be aware that the pharmaceutical companies have been ruthlessly increasing the cost of life sustaining insulin far beyond the actual cost of production. Insulin prices can range from $334 to $1,000 a month in the U.S., according to a 2020 Kaiser Family Foundation report. Americans typically pay about 10 times more than people from 32 other countries, according to a 2020 government survey. Thankfully the federal goverment has finally stepped up to put a stop to this. Starting January 1st, 2023, the cost of insulin for Medicare patients will be capped at no more than $35 per month. Unfortunately, this law does not apply to private health insurers. But it is progress. Other hopeful avenues are emerging: The state of California is investing in making their own low-cost insulin and a non-profit company is hoping to bring affordable insulin to the market. These two plans could potentially bestow on some who require insulin the kind of insulin accessibility that patients in all other high-income countries enjoy.


 
 
 

Recent Posts

See All

Comments


GNA_2020_Member_Badge.png
BAHCA logo

Raye Elaine BCPA

P.O. Box 2730
Sebastopol, Ca 95473

rayeelaine.info

raye@rayeelaine.info

(707) 535-9941

(707) 921-7936 fax

PAC Board Certified Logo
  • Facebook

DISCLAIMER

Raye Elaine, BCPA does not provide legal, medical, accounting or financial advisory services. 
If you need help with any of those services, please seek help from the appropriate professional. 

bottom of page